Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer | Zendy

AI Assistant Blog Pricing

Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.